he risk of a recurrence of breast cancer continues for an indefinite period after surgery, radiation, and medical therapy. 1, 2 Since the growth of breast cancer depends on the action of estrogen, 3 long-term reductions in the risk of recurrence have been achieved by antagonizing the activity of estrogen with the selective estrogen-receptor modulator tamoxifen in women with hormone-receptor-positive tumors. 1, 2 The postoperative administration of tamoxifen for five years reduces the risk of recurrence by 47 percent and reduces the risk of death by 26 percent. 2, 4 However, in a trial conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), women who continued to receive tamoxifen therapy after five years had worse outcomes than women in whom it was discontinued at five years. 5, 6 On the basis of these results, the National Cancer Institute has recommended that, outside of a clinical trial, tamoxifen treatment should be limited to five years. 7 Tamoxifen is both an antagonist and a partial agonist of the estrogen receptor. 8 Over time, its agonist action may become exaggerated and thereby impair its potential anticancer activity. It is known that resistance to tamoxifen and dependence on its estrogen-agonist effects develop in breast-cancer cells that are cultured in the presence of tamoxifen. [9] [10] [11] [12] [13] [14] [15] [16] [17] In women with metastatic disease that progresses despite tamoxifen therapy, aromatase (estrogen synthetase) inhibitors, including letrozole, have demonstrated efficacy. 18, 19 In this study of postmenopausal women who had been treated for early-stage breast cancer, we investigated whether letrozole would have antitumor effects after 4.5 to 6 years of tamoxifen therapy had been completed. We report the results of our first planned interim analysis. After reviewing the information presented here, the data and safety monitoring committee recommended that, in the interest of patient care, the study be discontinued early, and the participants informed of the results. These actions were taken immediately before this article was published.
study design
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of letrozole in postmenopausal women with primary breast cancer who had completed approximately 5 years (range, 4.5 to 6) of adjuvant tamoxifen therapy. Women were randomly assigned to receive letrozole (2.5 mg) or placebo orally daily for five years. Women were stratified according to the tumor hormone-receptor status (positive or unknown), lymph-node status (negative, positive, or unknown), and receipt or nonreceipt of previous adjuvant chemotherapy. The primary end point was disease-free survival, defined as the time from randomization to the recurrence of the primary disease (in the breast, chest wall, or nodal or metastatic sites) or the development of a new primary breast cancer in the contralateral breast. Secondary cancer and death without a recurrence or a diagnosis of contralateral breast cancer were not included as events in this analysis.
The secondary end points included overall survival (defined as the time to death from any cause), quality of life, and long-term safety. Adverse events were assessed according to the Common Toxicity Criteria of the National Cancer Institute (version 2.0). Quality of life was assessed by means of the Medical Outcomes Study 36-Item Short Form General Health Survey (SF-36) and the Menopause-Specific Quality of Life (MENQOL) questionnaire. 20, 21 Companion studies assessed the lipid profile and the bone mineral density annually.
The institutional review board of each participating institution approved the study protocol. All patients gave written informed consent.
study population
Women were eligible if they were at least 50 years of age at the start of adjuvant tamoxifen therapy, if they were younger than 50 years but were postmenopausal at the initiation of tamoxifen therapy, if they were younger than 50 years at the start of tamoxifen therapy but had undergone bilateral oophorectomy, if they were premenopausal and younger than 50 years of age at the start of tamoxifen therapy but became amenorrheic during chemotherapy or treatment with tamoxifen, of if they had postmenopausal levels of luteinizing hormone or follicle-stimulating hormone. Other criteria for eligibility included the following: previous adjuvant tamoxifen therapy lasting 4.5 to 6 years; histologically confirmed primary breast cancer; a tumor that was positive for estrogen receptors, progesterone receptors, or both (defined by a level of 10 fmol per milligram of protein or a positive result on immunohistochemical analysis or estrogen-receptor or progesterone-receptor immunocytochemical analysis); discontinuation of tamoxifen therapy less than 3 months before enrollment; an Eastern Cooperative Oncology Group perform-ance status of 0, 1, or 2 (scored on a scale of 0 to 5, with lower scores indicating better function); and a life expectancy of more than 5 years. Imaging studies were performed to rule out metastatic disease only in women who were symptomatic or had abnormal blood tests.
Criteria for exclusion were the concurrent use of investigational drugs and a history of or the presence of another type of cancer other than skin cancer or carcinoma in situ of the cervix. Concomitant systemic hormone-replacement therapy or concomitant treatment with a selective estrogen-receptor modulator was contraindicated. Intermittent treatment with vaginal estrogens was permitted.
study procedures
Women were randomly assigned to treatment groups with the use of the minimization method. 22 They were assessed at one month, through telephone interviews, for compliance and toxic effects. Clinical evaluation, routine blood work, and evaluation of toxic effects were performed semiannually during year 1 and annually thereafter; mammography was performed annually throughout the study. At base line, women reported previous diagnoses of bone fractures, osteoporosis, or cardiovascular disease. Subsequently, new diagnoses were reported by women at follow-up visits. Treatment was discontinued if there was serious intercurrent illness, unacceptable toxic effects, or a recurrence of disease or at the request of the patient. SF-36 and MENQOL questionnaires were completed by a subgroup of women. Recurrence of disease was defined pathologically or on the basis of clinical or radiologic findings, and recurrences were dated at the time they were first detected.
Interim safety analyses were reviewed twice yearly by the data and safety monitoring committee. Funding was provided by the Canadian Cancer Society, the U.S. National Cancer Institute, and Novartis Pharmaceuticals. Data were collected, managed, and analyzed by the National Cancer Institute of Canada Clinical Trials Group. The trial committee made the decision to publish the results.
statistical analysis
The sample size was calculated under the assumptions of a four-year disease-free survival rate of 88 percent in the placebo group and the detection of a difference of 2.5 percent in the four-year diseasefree survival rate (hazard ratio for local or metastatic recurrence of the disease or the diagnosis of contralateral breast cancer, 0.78), with 80 percent power at a two-sided alpha level of 0.05. These assumptions necessitated the enrollment of 4800 women over a four-year period with two years of follow-up, accounting for 515 events.
Two interim analyses were to be conducted, after 171 and 342 events had occurred. Early termination would be considered at the time of the interim analyses if the P value of the stratified log-rank test was below a nominal significance level calculated with the use of the Lan-DeMets alpha spending function, with O'Brien-Fleming boundaries that maintained the overall significance of the study at a two-sided alpha level of 0.05. 23 The required minimal number of events for the first interim analysis (171) had occurred by March 2003. This report is based on the results presented to the data and safety monitoring committee on August 22, 2003 ; it includes data on efficacy through August 19, 2003 , and data on adverse events through February 28, 2003 . Disease-free survival and overall survival were the two efficacy end points considered in the interim analysis. For the analysis of disease-free survival, data for the women who died without a recurrence of breast cancer or a new diagnosis of contralateral primary breast cancer were censored at the date of death. The stratified log-rank test, taking into account the stratification factors used for randomization, was used for the comparison of the treatment groups in terms of diseasefree and overall survival. 24 The chi-square test was used for the comparison of the groups in terms of the rates of toxic effects. All reported P values are two-sided.
study population
Between August 1998 and September 2002, 5187 women underwent randomization; 2593 were assigned to the letrozole group, and 2594 to the placebo group. In order to complete accrual to a substudy focused on effects on bone, enrollment exceeded the planned 4800 women. Thirty women (18 in the letrozole group and 12 in the placebo group) who did not have investigation forms at base line were excluded from the analyses. Thirty-nine women (19 in the letrozole group and 20 in the placebo group) were deemed ineligible because they had received adjuvant tamoxifen therapy for too long, too much time had elapsed since their discontinuation of such therapy, their menopausal status did not meet the The new england journal of medicine eligibility criteria, they had had a previous recurrence, they currently had or had previously had another type of cancer, their primary surgery had been inadequate, they had a hormone-receptor-negative tumor, they had inadequate investigations at base line, or they were receiving simultaneous hormone therapy. These women were included in the analysis according to the intention-to-treat principle. The two groups were balanced in terms of all relevant base-line characteristics (Table 1) .
study outcome
At a median follow-up of 2.4 years in this first analysis, 207 events (40 percent of the events required for the final analysis) had occurred. With this number of events, the O'Brien-Fleming boundary was 0.0008. Figure 1A shows the Kaplan-Meier curves for disease-free survival in the two groups. The estimated four-year disease-free survival rate was 93 percent in the letrozole group and 87 percent in the placebo group. The hazard ratio for a local or metastatic recurrence or new contralateral breast cancer in the letrozole group as compared with the placebo group was 0.57 (95 percent confidence interval, 0.43 to 0.75; P=0.00008). We also performed a sensitivity analysis in which we counted the deaths of women who did not have a recurrence or contralateral breast cancer as events in the estimation of diseasefree survival, instead of censoring the data for these women. In this analysis, the hazard ratio for death, In an unplanned subgroup analysis, the effect of letrozole was at least as great among women with node-negative disease (hazard ratio for recurrence or contralateral breast cancer, 0.47; P=0.005) as among those with node-positive disease (hazard ratio, 0.60; P=0.003). Table 2 shows the sites of recurrence; there were fewer locoregional and distant recurrences and fewer new primary tumors in the contralateral breast in the letrozole group than in the placebo group.
Among the 25 women who had only local recurrences in the ipsilateral breast, 4 had ductal or lobular carcinoma in situ (all in the placebo group), and among the 40 women in whom new primary tumors developed in the contralateral breast, 6 had ductal or lobular carcinoma in situ (1 in the letrozole group and 5 in the placebo group). Seventy-three deaths have been reported (31 in the letrozole group and 42 in the placebo group) ( Table 3 and Fig. 1B) . The estimated four-year overall survival rate was 96 percent in the letrozole group and 94 percent in the placebo group. The hazard ratio for death from any cause in the letrozole group as compared with the placebo group was 0.76 (95 percent confidence interval, 0.48 to 1.21; P=0.25). Table 4 shows the rates of diseasefree survival and overall survival through year 4.
safety Table 5 shows data on safety and toxic effects in the first 4299 women enrolled in the study. Toxic effects * "Missing data" are data that were not reported; "unknown" represents data that were reported as unknown. The new england journal of medicine were primarily of grade 1 or 2. Hot flashes, arthritis, arthralgia, and myalgia were more common in the letrozole group than in the placebo group (P<0.05 for all comparisons). Vaginal bleeding was more common in the placebo group (P=0.01). A total of 4.5 percent of the women in the letrozole group discontinued the study treatment because of toxic effects, as compared with 3.6 percent of the women in the placebo group; the difference was not significant (P=0.11). Approximately equal numbers of women in the letrozole group (256) and the placebo group (254) chose to discontinue treatment.
There was a trend toward a higher rate of reports of newly diagnosed osteoporosis in the letrozole group than in the placebo group (P=0.07). Slightly more women in the letrozole group had at least one cardiovascular event or new bone fracture, but neither difference between the groups was significant (P=0.40 and P=0.24, respectively).
We compared therapy with letrozole, an aromatase inhibitor, with a placebo in healthy women with previously treated early breast cancer. The study treatment was given from years 5 through 10 after the diagnosis -a period when further tamoxifen therapy is not beneficial but when relapses of breast cancer occur. 5, 6 Several other trials comparing aromatase inhibitors with tamoxifen as adjuvant therapy for the first five years after diagnosis or studying aromatase inhibitors used in sequence with tamoxifen are under way. 25 Preliminary results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial show that disease-free survival is longer with anastrozole than with tamoxifen, 26 although tamoxifen therapy is still considered an acceptable standard of care. 27,28 discussion 
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We found a significant improvement in diseasefree survival, including a substantial reduction in the rate of distant metastasis in the letrozole group as compared with the placebo group; the rate of death due to breast cancer was almost halved. Letrozole was equally effective in women with node-negative disease and those with node-positive disease. The reduction in the rates of recurrent and new disease in the letrozole group confirms the continuous dependence of hormone-receptor-positive breast cancer on estrogen.
The data and safety monitoring committee concluded that the results concerning disease-free survival would in themselves have necessitated the unblinding of the study. In addition, the trend toward a reduction in overall mortality in the letrozole group, albeit not statistically significant, influenced the members of the committee to recommend that this information be made available expeditiously. This step was taken immediately before the publication of this article.
The reduction in the frequency of new primary tumors in the contralateral breast (a relative reduction of 46 percent), a secondary end point of our trial, is compatible with the reduction in the frequency of contralateral disease among women who received adjuvant tamoxifen therapy in earlier studies, 2 as well as the reductions among women in the NSABP tamoxifen prevention trial 29 and those in the ATAC trial. 26 Tamoxifen provides protection against bone fractures and lowers serum cholesterol levels. [30] [31] [32] In contrast, aromatase inhibitors, by decreasing estrogen levels, may reduce bone mineral density and cause hypercholesterolemia. Studies of the effects of letrozole on plasma lipids have had conflicting results. 33, 34 We found a nonsignificant difference in the rate of cardiovascular events between the letrozole group (4.1 percent) and the placebo group (3.6 percent), and there were no reports of drug-related hypercholesterolemia. Longer follow-up is needed to rule out the possibility that letrozole has adverse cardiovascular effects. Ongoing monitoring for toxic effects in women receiving letrozole therapy and analysis of our lipid substudy are planned.
Estrogen deficiency is associated with menopausal osteoporosis. 35 Both anastrozole and letrozole have been shown to increase bone resorption, 26,36,37 but they have not been associated with osteoporosis. In our study, more women in the letrozole group than in the placebo group reported diagnoses of new-onset osteoporosis, and fractures occurred in a few more women in the letrozole group than in the placebo group (3.6 percent and 2.9 percent, respectively). Because of the early discontinuation of our study, however, these data may underestimate the long-term effects of letrozole on bone metabolism. The effectiveness of adding bisphosphonates to aromatase inhibitors is under evaluation. Until the results of this evaluation become available, we recommend that women receiving long-term letrozole therapy take calcium and vitamin D according to the guidelines for the prevention of osteoporosis and that their physicians consider monitoring their bone mineral density.
Hot flashes, arthritis, arthralgia, and myalgia, although more common with letrozole, were generally low-grade. Few women discontinued the study treatment because of toxic effects. The consequences of these effects should be clarified by analyses * CI denotes confidence interval. The new england journal of medicine of our data on quality of life, but because of the early termination of our study, we could not present these data here. Endometrial cancer is in part an estrogen-dependent cancer and represents a rare complication of tamoxifen therapy that may occur even after the discontinuation of treatment with the drug. 29, 38, 39 Vaginal bleeding was significantly less frequent in the letrozole group than in the placebo group in our study, and future studies to determine whether letrozole reduces the risk of endometrial cancer will be of interest. Letrozole therapy resulted in a significant improvement in disease-free survival, which included a reduction in the frequency of new primary tumors in the contralateral breast; this reduction accounted for 21 percent of the difference in events between the treatment groups (12 of 57 events). The rates of distant recurrence of disease and death due to breast cancer were also lower in the letrozole group than in the placebo group.
On the basis of these findings, postmenopausal women with hormone-receptor-positive tumors who have completed about five years of adjuvant tamoxifen therapy should be considered for letrozole treatment. However, our results, which necessitated the discontinuation of the study, leave the optimal duration of treatment undefined and the question of long-term toxicity unanswered. Data from other, ongoing aromatase-inhibitor trials will contribute information regarding toxic effects, but the question of the optimal duration of treatment will not be answered by the current trials. Our study did not address the efficacy of letrozole therapy in women in whom tamoxifen therapy had been discontinued more than three months earlier, but because there was an ongoing reduction in the hazard of recurrence in the letrozole group, the use of the drug in such women should be considered. Consequently, our trial committee has recommended that women in the placebo group in our study discuss their personal risk profile with their oncologist and be considered for letrozole therapy. Our results do not apply to premenopausal women, since therapy with aromatase inhibitors alone does not suppress estrogen production adequately in women who are still ovulating. 40 These results show that in postmeno-* Data are for adverse events whose incidence in the two groups differed by more than 1 percent or whose incidence was at least 10 percent in either group. Grades are according to the Common Toxicity Criteria of the National Cancer Institute, version 2.0. Data on clinical fractures, cardiovascular events, and osteoporosis were available for 2166 women in the letrozole group and 2157 women in the placebo group. pausal women, letrozole therapy significantly improves disease-free survival.
